Recombinant Mouse ACE2 Protein，His

Angiotensin-converting enzyme 2 (ACE2) is a crucial enzyme in the renin-angiotensin system, which plays a significant role in regulating blood pressure and maintaining fluid balance. Beyond its physiological functions, ACE2 has gained prominence in recent years due to its role as the primary receptor for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19. The binding of the viral spike protein to ACE2 facilitates viral entry into host cells, making ACE2 a target for therapeutic intervention and vaccine development. Researchers have been focusing on recombinant ACE2 proteins, which are engineered versions of the native enzyme, as potential treatments for COVID-19. These recombinant proteins can act as decoys that bind to the virus, thereby preventing it from attaching to human cells. The engineering of ACE2 has allowed for modifications that enhance its stability, binding affinity, and therapeutic potential. Additionally, studies have explored the systemic effects of ACE2, suggesting that enhancing its activity can mitigate acute lung injury and promote cardiovascular health. The ongoing research into ACE2 recombinant proteins is crucial for developing new strategies to combat COVID-19 and understanding their broader implications in cardiovascular and respiratory diseases.